Clinical Trial Update: Bioequivalence of Two Insulatard® Formulations in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing two Insulatard insulin formulations in healthy subjects. The sponsor is Novo Nordisk A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Insulatard (insulin isophane)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED